Major investors are increasingly focusing on AI-driven biology and longevity, with startups like NewLimit tripling in value. While many of these startups remain private, NVIDIA and Eli Lilly stand out as the main public companies involved, partnering to industrialize drug discovery through a $1 billion AI lab. NVIDIA provides the computing backbone, while Eli Lilly applies AI to drug development, both showing strong financial growth. Investors interested in programmable biology should consider these two stocks, though valuations are high, and caution is advised.
Nvidia's Board approved a 25-fold increase in its quarterly dividend to $0.25 per share, payable June 26, 2026, reflecting the company's strong financial performance. This dividend hike follows record Q1 fiscal 2027 revenue of $81.6 billion, driven b...
Alphabet announced it will raise $80 billion through equity offerings to fund its growing artificial intelligence infrastructure. This move has caused volatility but also sparked a rally in technology and semiconductor stocks. While many hardware com...
AMD, Intel, and Nvidia are showing positive momentum in early trading, driven by ongoing enthusiasm for AI technology. AMD is expected to jump about $15, aiming for a $600 target with $480 as a short-term support level. Intel is forecasted to rise ar...
NVIDIA expanded its strategic partnership with Synopsys through a $2 billion investment, reinforcing their collaboration in AI chip design. Synopsys, which provides essential software tools for NVIDIA's chip production, is benefiting from strong reve...
NVIDIA and AMD both lead in AI chip markets but differ greatly for retirement investors. NVIDIA trades at a more reasonable valuation with a PEG of 0.68 versus AMD's 1.09, and shows faster growth with Q1 fiscal 2027 revenue up 85% year-over-year. NVI...
